{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"GKOS","limit":50},"count":50,"signals":[{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":97,"context":"ne learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences to our business. Failure to comply with data privacy and security laws could have a material adverse effect on our business. Our net operating loss tax carryforwards may not be available, or may be subject to certain limitations, to offset future taxable income. Risks Related to Financing Transactions The","filed_date":"2026-02-23","accession":"0001193125-26-061944","full_text":"https://origin.rootz.global/static/filing/0001193125-26-061944.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":32,"context":"idents, service interruptions, or data corruption could materially disrupt our operations and adversely affect our business. | | | | Failure to comply with data privacy and security laws could have a material adverse effect on our business. | | | | Our net operating loss tax carryforwards may not be available, or may be subject to certain limitations, to offset future taxable income. | | *Risks Related to Our Indebtedne","filed_date":"2025-10-31","accession":"0001104659-25-104529","full_text":"https://origin.rootz.global/static/filing/0001104659-25-104529.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":32,"context":"idents, service interruptions, or data corruption could materially disrupt our operations and adversely affect our business. | | | | Failure to comply with data privacy and security laws could have a material adverse effect on our business. | | | | Our net operating loss tax carryforwards may not be available, or may be subject to certain limitations, to offset future taxable income. | | *Risks Related to Our Indebtedne","filed_date":"2025-08-04","accession":"0001558370-25-010113","full_text":"https://origin.rootz.global/static/filing/0001558370-25-010113.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":32,"context":"idents, service interruptions, or data corruption could materially disrupt our operations and adversely affect our business. | | | | Failure to comply with data privacy and security laws could have a material adverse effect on our business. | | | | Our net operating loss tax carryforwards may not be available, or may be subject to certain limitations, to offset future taxable income. | | *Risks Related to Our Indebtedne","filed_date":"2025-05-01","accession":"0001558370-25-006041","full_text":"https://origin.rootz.global/static/filing/0001558370-25-006041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":34,"context":"trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; our ability to protect, and the expense and time-consuming nature of protecting,","filed_date":"2025-04-15","accession":"0001558370-25-004839","full_text":"https://origin.rootz.global/static/filing/0001558370-25-004839.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":46,"context":"irtual Annual MeetingHow do I attend the Virtual Annual Meeting? to learn more about attending the Annual Meeting | | | | | | | | | 2 | Approve, on an advisory basis, the compensation of the Companys named executive officers; | | | | | 3 | Ratify the appointment of Ernst & Young LLP as the Companys independent registered public accounting firm for the year ending December 31, 2025; and | | | | 4 | Transact such other bu","filed_date":"2025-04-15","accession":"0001558370-25-004839","full_text":"https://origin.rootz.global/static/filing/0001558370-25-004839.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":89,"context":"idents, service interruptions, or data corruption could materially disrupt our operations and adversely affect our business. | | | | Failure to comply with data privacy and security laws could have a material adverse effect on our business. | | | | Our net operating loss tax carryforwards may not be available, or may be subject to certain limitations, to offset future taxable income. | | *Risks Related to Our Indebtedne","filed_date":"2025-02-25","accession":"0001558370-25-001402","full_text":"https://origin.rootz.global/static/filing/0001558370-25-001402.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":29,"context":"idents, service interruptions, or data corruption could materially disrupt our operations and adversely affect our business. | | | | Failure to comply with data privacy and security laws could have a material adverse effect on our business. | | | | Our net operating loss tax carryforwards may not be available to offset future taxable income. | | *Risks Related to Our Indebtedness* | | Our debt service obligations could","filed_date":"2024-11-05","accession":"0001558370-24-014295","full_text":"https://origin.rootz.global/static/filing/0001558370-24-014295.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":29,"context":"idents, service interruptions, or data corruption could materially disrupt our operations and adversely affect our business. | | | | Failure to comply with data privacy and security laws could have a material adverse effect on our business. | | | | Our net operating loss tax carryforwards may not be available to offset future taxable income. | | *Risks Related to Our Indebtedness* | | Our debt service obligations could","filed_date":"2024-08-02","accession":"0001558370-24-010729","full_text":"https://origin.rootz.global/static/filing/0001558370-24-010729.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":29,"context":"idents, service interruptions, or data corruption could materially disrupt our operations and adversely affect our business. | | | | Failure to comply with data privacy and security laws could have a material adverse effect on our business. | | | | Our net operating loss tax carryforwards may not be available to offset future taxable income. | | *Risks Related to Our Indebtedness* | | Our debt service obligations could","filed_date":"2024-05-03","accession":"0001558370-24-006573","full_text":"https://origin.rootz.global/static/filing/0001558370-24-006573.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":34,"context":"ommunityAverage age of directors is 59Two new directors added in 2021 | | | Active Board Oversight and Engagement | | Robust oversight of risks related to the Companys business, including compliance, cybersecurity and ESG risksDirectors attended an average of 99% of Board and Committee meetings in 2023; Chair and Lead Independent Director attended 100% of Board and Committee meetingsOverboarding guidel","filed_date":"2024-04-16","accession":"0001558370-24-005203","full_text":"https://origin.rootz.global/static/filing/0001558370-24-005203.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":90,"context":"os Corporation Amended and Restated 2015 Omnibus Incentive Compensation Plan; | | | | | | | | 3 | Approve, on an advisory basis, the frequency of future advisory votes on compensation of the Companys named executive officers; | | | | | 4 | Approve, on an advisory basis, the compensation of the Companys named executive officers; | | | | 5 | Ratify the appointment of Ernst & Young LLP as the Companys independent registere","filed_date":"2024-04-16","accession":"0001558370-24-005203","full_text":"https://origin.rootz.global/static/filing/0001558370-24-005203.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":85,"context":"idents, service interruptions, or data corruption could materially disrupt our operations and adversely affect our business. | | | | Failure to comply with data privacy and security laws could have a material adverse effect on our business. | | | | Our net operating loss tax carryforwards may not be available to offset future taxable income. | | *Risks Related to Our Indebtedness* | | Our debt service obligations could","filed_date":"2024-02-23","accession":"0001558370-24-001630","full_text":"https://origin.rootz.global/static/filing/0001558370-24-001630.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ting cash and cash equivalents to the extent those funds are not insured or otherwise protected by the FDIC. Continuation or worsening of these unfavorable global and regional conditions could have a material adverse effect on our operations and cause us to need to seek additional capital. Public health crises, such as the COVID-19 pandemic, have adversely affected, and could in the future adversely affect, our business","filed_date":"2023-11-01","accession":"0001558370-23-017253","full_text":"https://origin.rootz.global/static/filing/0001558370-23-017253.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":17,"context":"to the extent those funds are not insured or otherwise protected by the FDIC. Any delay in our ability to access our cash and cash equivalents (or the loss of some or all of such funds) could have a material adverse effect on our operations and cause us to need to seek additional capital. Public health crises, such as the COVID-19 pandemic, have adversely affected, and could in the future adversely affect, our business","filed_date":"2023-08-02","accession":"0001558370-23-012950","full_text":"https://origin.rootz.global/static/filing/0001558370-23-012950.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":17,"context":"to the extent those funds are not insured or otherwise protected by the FDIC. Any delay in our ability to access our cash and cash equivalents (or the loss of some or all of such funds) could have a material adverse effect on our operations and cause us to need to seek additional capital. 32 [Table of Contents](#TOC) Public health crises, such as the COVID-19 pandemic, have adversely affected, and could in the future a","filed_date":"2023-05-04","accession":"0001558370-23-008148","full_text":"https://origin.rootz.global/static/filing/0001558370-23-008148.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":27,"context":"ing our *iStent* family of products in combination with cataract surgery, which were announced in mid-2021 and went into effect on January 1, 2022. The announcement of the reduced payment rates had a material adverse impact on our U.S. glaucoma sales in the third and fourth quarters of 2021, an impact which was expected to continue, and increase, throughout 2022. The 2022 sales target set by the CNG Committee for purpos","filed_date":"2023-04-18","accession":"0001558370-23-006164","full_text":"https://origin.rootz.global/static/filing/0001558370-23-006164.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":97,"context":"il the Companys 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified; | | | | | 2 | Approve, on an advisory basis, the compensation of the Companys named executive officers; | | | | | 3 | Ratify the appointment of Ernst & Young LLP as the Companys independent registered public accounting firm for the year ending December 31, 2023; and | | | | | 4 | Transact such other","filed_date":"2023-04-18","accession":"0001558370-23-006164","full_text":"https://origin.rootz.global/static/filing/0001558370-23-006164.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":17,"context":"entional acts of vandalism or fraud by third  20 [Table of Contents](#Toc) parties and sabotage. While none of the cyber incidents or service interruptions that we have experienced to date have had a material adverse impact on our business, financial condition or operations, we cannot assure that future incidents will not materially and adversely impact us. In addition, some of our software systems are cloud-based data","filed_date":"2023-02-24","accession":"0001558370-23-002070","full_text":"https://origin.rootz.global/static/filing/0001558370-23-002070.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":14,"context":"rs with access privileges, intentional acts of vandalism or fraud by third parties and sabotage. While none of the cyber incidents or service interruptions that we have experienced to date have had a material adverse impact on our business, financial condition or operations, we cannot assure that future incidents will not materially and adversely impact us. In addition, a variety of our software systems are cloud-based","filed_date":"2022-11-04","accession":"0001558370-22-016317","full_text":"https://origin.rootz.global/static/filing/0001558370-22-016317.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":14,"context":"rs with access privileges, intentional acts of vandalism or fraud by third parties and sabotage. While none of the cyber incidents or service interruptions that we have experienced to date have had a material adverse impact on our business, financial condition or operations, we cannot assure that future incidents will not materially and adversely impact us. In addition, a variety of our software systems are cloud-based","filed_date":"2022-08-05","accession":"0001558370-22-012314","full_text":"https://origin.rootz.global/static/filing/0001558370-22-012314.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":14,"context":"rs with access privileges, intentional acts of vandalism or fraud by third parties and sabotage. While none of the cyber incidents or service interruptions that we have experienced to date have had a material adverse impact on our business, financial condition or operations, we cannot assure that future incidents will not materially and adversely impact us. In addition, a variety of our software systems are cloud-based","filed_date":"2022-05-05","accession":"0001558370-22-007455","full_text":"https://origin.rootz.global/static/filing/0001558370-22-007455.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":27,"context":"lth Policy | | | | | | | | | | | | International Commercialization | | | | | | | | | | | | Medtech | | | | | | | | | | | | Ophthalmology | | | | | | | | | | | | Pharmaceutical | | | | | | | | | | | | Cybersecurity | | | | | | | | | | | | | | | | GLAUKOS CORPORATION|2022 PROXY STATEMENT11 | | [Table of Contents](#Toc) CORPORATE GOVERNANCE **Corporate Governance Guidelines** Our Board of Directors, on th","filed_date":"2022-04-19","accession":"0001558370-22-005588","full_text":"https://origin.rootz.global/static/filing/0001558370-22-005588.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":81,"context":"irectors until the Companys 2025 annual meeting of stockholders and until their respective successors are duly elected and qualified;(2)Approve, on an advisory basis, the compensation of the Companys named executive officers;(3)Ratify the appointment of Ernst & Young LLP as the Companys independent registered public accounting firm for the year ending December 31, 2022; and(4)Transact such other business as may properly","filed_date":"2022-04-19","accession":"0001558370-22-005588","full_text":"https://origin.rootz.global/static/filing/0001558370-22-005588.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":15,"context":"rs with access privileges, intentional acts of vandalism or fraud by third parties and sabotage. While none of the cyber incidents or service interruptions that we have experienced to date have had a material adverse impact on our business, financial condition or operations, we cannot assure that future incidents will not materially and adversely impact us. In addition, a variety of our software systems are cloud-based","filed_date":"2022-02-28","accession":"0001558370-22-002371","full_text":"https://origin.rootz.global/static/filing/0001558370-22-002371.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":9,"context":"ed sales, increased overhead costs, product shortages, loss or misuse of proprietary or confidential information, intellectual property or sensitive or personal information, all of which could have a material adverse effect on our reputation, business, financial condition and operating results.  Failure to comply with data privacy and security laws could have a material adverse effect on our business. We are subject to","filed_date":"2021-11-08","accession":"0001558370-21-015090","full_text":"https://origin.rootz.global/static/filing/0001558370-21-015090.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":9,"context":"ed sales, increased overhead costs, product shortages, loss or misuse of proprietary or confidential information, intellectual property or sensitive or personal information, all of which could have a material adverse effect on our reputation, business, financial condition and operating results.  Failure to comply with data privacy and security laws could have a material adverse effect on our business. We are subject to","filed_date":"2021-08-05","accession":"0001558370-21-010606","full_text":"https://origin.rootz.global/static/filing/0001558370-21-010606.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":7,"context":"ed sales, increased overhead costs, product shortages, loss or misuse of proprietary or confidential information, intellectual property or sensitive or personal information, all of which could have a material adverse effect on our reputation, business, financial condition and operating results.  Failure to comply with data privacy and security laws could have a material adverse effect on our business. We are subject to","filed_date":"2021-05-06","accession":"0001558370-21-006261","full_text":"https://origin.rootz.global/static/filing/0001558370-21-006261.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":92,"context":"irectors until the Companys 2024 annual meeting of stockholders and until their respective successors are duly elected and qualified;(2)Approve, on an advisory basis, the compensation of the Companys named executive officers;(3)Ratify the appointment of Ernst & Young LLP as the Companys independent registered public accounting firm for the year ending December 31, 2021; and(4)Transact such other business as may properly","filed_date":"2021-04-22","accession":"0001558370-21-004648","full_text":"https://origin.rootz.global/static/filing/0001558370-21-004648.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":8,"context":"ed sales, increased overhead costs, product shortages, loss or misuse of proprietary or confidential information, intellectual property or sensitive or personal information, all of which could have a material adverse effect on our reputation, business, financial condition and operating results.  Failure to comply with data privacy and security laws could have a material adverse effect on our business. We are subject to","filed_date":"2021-03-01","accession":"0001558370-21-002061","full_text":"https://origin.rootz.global/static/filing/0001558370-21-002061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"n to adopt our products. Accordingly, changes in the payment the physician receives could affect the extent to which physicians recommend procedures using our products to patients, which could have a material adverse effect on our business, financial condition and operating results. Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of contro","filed_date":"2020-11-05","accession":"0001558370-20-012925","full_text":"https://origin.rootz.global/static/filing/0001558370-20-012925.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"n to adopt our products. Accordingly, changes in the payment the physician receives could affect the extent to which physicians recommend procedures using our products to patients, which could have a material adverse effect on our business, financial condition and operating results. Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of contro","filed_date":"2020-08-07","accession":"0001558370-20-009980","full_text":"https://origin.rootz.global/static/filing/0001558370-20-009980.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":9,"context":"n to adopt our products. Accordingly, changes in the payment the physician receives could affect the extent to which physicians recommend procedures using our products to patients, which could have a material adverse effect on our business, financial condition and operating results. Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of contro","filed_date":"2020-05-07","accession":"0001558370-20-005773","full_text":"https://origin.rootz.global/static/filing/0001558370-20-005773.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"-generation trabecular bypass device, iStent inject. We made considerable progress on advancing our glaucoma pipeline by advancing several key clinical trials, most notably with continued patient enrollment in our iDose phase 3 clinical program and patient enrollment completion in the pivotal study for iStent infinite. We also secured an exclusive agreement with Santen, Inc. to distribute its PRESERF","filed_date":"2020-04-24","accession":"0001558370-20-004239","full_text":"https://origin.rootz.global/static/filing/0001558370-20-004239.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":121,"context":", we acquired Avedro, Inc., a leader in treating keratoconus and related corneal disorders and refractive conditions. Avedro will serve as the cornerstone of our new corneal health franchise. We also entered into licensing arrangement with Intratus, Inc., which is developing breakthrough topical therapies for treating dry eye disease, and potentially glaucoma and other corneal disorders. This novel drug delivery platform adds to s","filed_date":"2020-04-24","accession":"0001558370-20-004239","full_text":"https://origin.rootz.global/static/filing/0001558370-20-004239.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"n to adopt our products. Accordingly, changes in the payment the physician receives could affect the extent to which physicians recommend procedures using our products to patients, which could have a material adverse effect on our business, financial condition and operating results. Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of contro","filed_date":"2020-03-02","accession":"0001558370-20-001862","full_text":"https://origin.rootz.global/static/filing/0001558370-20-001862.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":26,"context":"alifications, the accuracy of the representations and warranties of the parties and compliance by the parties with their respective obligations under the Merger Agreement; and (iv) the absence of any material adverse effect on Avedro or our company since the date of the Merger Agreement that is continuing. The closing of the Merger was also subject to the expiration or termination of any applicable waiting period under","filed_date":"2019-11-06","accession":"0001558370-19-010202","full_text":"https://origin.rootz.global/static/filing/0001558370-19-010202.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":26,"context":"ualifications, the accuracy of the representations and warranties of the parties and compliance by the parties with their respective obligations under the merger agreement; and (v) the absence of any material adverse effect on Avedro or our company since the date of the merger agreement that is continuing. We cannot provide assurance that these or the other conditions to the completion of the planned acquisition of Aved","filed_date":"2019-08-08","accession":"0001558370-19-007578","full_text":"https://origin.rootz.global/static/filing/0001558370-19-007578.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":25,"context":"ce may not be available on commercially reasonable terms to cover certain of these catastrophic events. In addition, regardless of the level of insurance coverage, damage to our facilities may have a material adverse effect on our business, financial condition and operating results. Additionally, if we are unable to continue to expand our manufacturing facility in compliance with regulatory requirements or to hire addit","filed_date":"2019-05-08","accession":"0001558370-19-004488","full_text":"https://origin.rootz.global/static/filing/0001558370-19-004488.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"the last business day of 2018. In sum, we are pleased to report the following 2018 achievements: |  |  |  |  | |  Obtained FDA Approval of and Launched the iStent inject&#xAE; |  |  Began Patient Enrollment of Key Pivotal Studies |  | |  &#x221A; Received iStent inject approval in June 2018, approximately six months after premarket approval submission &#x221A; Executed iStent inject commercial launch","filed_date":"2019-04-17","accession":"0001558370-19-003060","full_text":"https://origin.rootz.global/static/filing/0001558370-19-003060.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":118,"context":"Company&#x2019;s 2022 annual meeting of stockholders and until their respective successors are duly elected and qualified; (2) Approve, on an advisory basis, the compensation of the Company&#x2019;s named executive officers; (3) Ratify the appointment of Ernst & Young LLP as the Company&#x2019;s independent registered public accounting firm for the year ending December 31, 2019; and (4) Transact such other business as","filed_date":"2019-04-17","accession":"0001558370-19-003060","full_text":"https://origin.rootz.global/static/filing/0001558370-19-003060.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"d to reduce intraocular pressure by accessing an alternative drainage space within the eye and is being evaluated in combination with cataract surgery in a U.S. pivotal IDE trial, which completed enrollment in 2017. Similar in design to the iStent inject, the iStent SA is a two-stent product that uses a different autoinjection inserter and is designed for use in a standalone procedure. We are also pu","filed_date":"2019-02-28","accession":"0001558370-19-001235","full_text":"https://origin.rootz.global/static/filing/0001558370-19-001235.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":26,"context":"ment of profits, or civil or criminal investigations and penalties brought by FDA and the Department of Justice, or other governmental entities. Any agency or judicial enforcement action could have a material adverse effect on us. In order to obtain approval to market a drug product in the United States, a marketing application must be submitted to the FDA that includes data to establish the safety and effectiveness of","filed_date":"2019-02-28","accession":"0001558370-19-001235","full_text":"https://origin.rootz.global/static/filing/0001558370-19-001235.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":26,"context":"r delay. Failure of any of our suppliers to deliver products at the level our business requires would limit our ability to meet our sales commitments, which could harm our reputation and could have a material adverse effect on our business. We may also have difficulty obtaining similar components or drugs from other suppliers that are acceptable to the FDA or other regulatory agencies, and the failure of our suppliers t","filed_date":"2018-11-07","accession":"0001558370-18-008815","full_text":"https://origin.rootz.global/static/filing/0001558370-18-008815.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":25,"context":"r delay. Failure of any of our suppliers to deliver products at the level our business requires would limit our ability to meet our sales commitments, which could harm our reputation and could have a material adverse effect on our business. We may also have difficulty obtaining similar components or drugs from other suppliers that are acceptable to the FDA or other regulatory agencies, and the failure of our suppliers t","filed_date":"2018-08-06","accession":"0001558370-18-006456","full_text":"https://origin.rootz.global/static/filing/0001558370-18-006456.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":24,"context":"r delay. Failure of any of our suppliers to deliver products at the level our business requires would limit our ability to meet our sales commitments, which could harm our reputation and could have a material adverse effect on our business. We may also have difficulty obtaining similar components or drugs from other suppliers that are acceptable to the FDA or other regulatory agencies, and the failure of our suppliers t","filed_date":"2018-05-09","accession":"0001558370-18-004499","full_text":"https://origin.rootz.global/static/filing/0001558370-18-004499.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ecutive Officer payout based 50% on corporate objectives and 50% on individual objectives  &#xF0B7; Corporate goals are comprised of financial results, completion of clinical studies and clinical enrollment goals &#xF0B7; No payout unless threshold revenue goal is achieved &#xF0B7; Payout is capped at a maximum of 190% of base salary for Chief Executive Officer and 100% of base salary for other Named","filed_date":"2018-04-18","accession":"0001558370-18-003058","full_text":"https://origin.rootz.global/static/filing/0001558370-18-003058.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":96,"context":"9;s 2021 annual meeting of stockholders and until their respective successors are duly elected and qualified; |  | |  |  |  (2) Approve, on an advisory basis, the compensation of the Company&#x2019;s named executive officers; (3) Approve, on an advisory basis, the frequency of future advisory votes on executive compensation; (4) Ratify the appointment of Ernst & Young LLP as the Company&#x2019;s independent registered p","filed_date":"2018-04-18","accession":"0001558370-18-003058","full_text":"https://origin.rootz.global/static/filing/0001558370-18-003058.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":25,"context":"ment of profits, or civil or criminal investigations and penalties brought by FDA and the Department of Justice, or other governmental entities. Any agency or judicial enforcement action could have a material adverse effect on us. The steps required before a drug may be approved for marketing in the United States generally include: | | &#xB7; | | completion of preclinical laboratory tests and animal tests conducted in c","filed_date":"2018-02-28","accession":"0001558370-18-001301","full_text":"https://origin.rootz.global/static/filing/0001558370-18-001301.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GKOS","company":"GLAUKOS Corp","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":22,"context":"r delay. Failure of any of our suppliers to deliver products at the level our business requires would limit our ability to meet our sales commitments, which could harm our reputation and could have a material adverse effect on our business. We may also have difficulty obtaining similar components from other suppliers that are acceptable to the FDA or other regulatory agencies, and the failure of our suppliers to comply","filed_date":"2017-11-08","accession":"0001558370-17-008561","full_text":"https://origin.rootz.global/static/filing/0001558370-17-008561.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"f053866a0d13e7332fb12eb70c22ec5b61cd4ea48e69523b629b54717b3969f4","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"e59f4b79112584b5cda690b31a3c607117882f18fe841aea8a6c01127b749934","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":28,"hourly_limit":500,"remaining":472,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}